These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16835466)

  • 21. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.
    Muraki A; Miyashita K; Mitsuishi M; Tamaki M; Tanaka K; Itoh H
    J Appl Physiol (1985); 2012 Aug; 113(3):479-86. PubMed ID: 22653988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
    Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
    Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
    Turner NA; Midgley L; O'Regan DJ; Porter KE
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
    Melo AC; Valença SS; Gitirana LB; Santos JC; Ribeiro ML; Machado MN; Magalhães CB; Zin WA; Porto LC
    Int Immunopharmacol; 2013 Sep; 17(1):57-64. PubMed ID: 23747588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
    Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
    Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
    Nakata M; Nagasaka S; Kusaka I; Matsuoka H; Ishibashi S; Yada T
    Diabetologia; 2006 Aug; 49(8):1881-92. PubMed ID: 16685502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB.
    Lee DK; Park EJ; Kim EK; Jin J; Kim JS; Shin IJ; Kim BY; Lee H; Kim DE
    Cell Physiol Biochem; 2012; 30(3):499-511. PubMed ID: 22814256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition.
    Luzak B; Rywaniak J; Stanczyk L; Watala C
    Eur J Clin Invest; 2012 Aug; 42(8):864-72. PubMed ID: 22409214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
    Satoh K; Keimatsu N; Kanda M; Kasai T; Takaguri A; Sun F; Ichihara K
    Biol Pharm Bull; 2005 Nov; 28(11):2092-5. PubMed ID: 16272695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
    Austin PC; Mamdani MM
    Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
    Cho Y; Choe E; Lee YH; Seo JW; Choi Y; Yun Y; Wang HJ; Ahn CW; Cha BS; Lee HC; Kang ES
    Metabolism; 2015 Apr; 64(4):482-8. PubMed ID: 25312577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Not all statins interfere with clopidogrel during antiplatelet therapy.
    Mach F; Senouf D; Fontana P; Boehlen F; Reber G; Daali Y; de Moerloose P; Sigwart U
    Eur J Clin Invest; 2005 Aug; 35(8):476-81. PubMed ID: 16101667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
    Suzuki M; Kakuta H; Takahashi A; Shimano H; Tada-Iida K; Yokoo T; Kihara R; Yamada N
    J Atheroscler Thromb; 2005; 12(2):77-84. PubMed ID: 15942117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
    Mulhaupt F; Matter CM; Kwak BR; Pelli G; Veillard NR; Burger F; Graber P; Lüscher TF; Mach F
    Cardiovasc Res; 2003 Sep; 59(3):755-66. PubMed ID: 14499877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin.
    Murrow JR; Sher S; Ali S; Uphoff I; Patel R; Porkert M; Le NA; Jones D; Quyyumi AA
    J Clin Lipidol; 2012; 6(1):42-9. PubMed ID: 22264573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.